Market Eyes LiveSarepta Therapeutics,, Inc. (SRPT) Stock Rating & Analysis
MELANY's data-driven read on Sarepta Therapeutics,, Inc..
Why SRPT scores 54/100
MELANY scores Sarepta Therapeutics,, Inc. 54/100 by weighing eight factors. Here is how SRPT breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
- Avg EPS beat +83%
What Wall Street price targets and revisions are signalling.
- Analyst targets 29% upside
- Institutional net buying +28.6%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for SRPT
- Short interest 32% of float, high volatility risk on news
- Weak price momentum, trend not yet confirmed, may need more time to set up
Sector and theme context
Sarepta Therapeutics,, Inc. sits in the Healthcare sector theme, which MELANY currently rates 38/100 for strength. Theme strength feeds SRPT's momentum and catalyst factors above.
Tracking SRPT
Sarepta Therapeutics,, Inc. rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add SRPT to your watchlist and get alerted the moment the rating changes.
How MELANY rates SRPT
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Sarepta Therapeutics,, Inc.'s 54/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about SRPT
Is Sarepta Therapeutics,, Inc. (SRPT) a buy?
As of 2026-08-10, MELANY rated Sarepta Therapeutics,, Inc. Hold with a composite score of 54/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Sarepta Therapeutics,, Inc.'s MELANY score?
Sarepta Therapeutics,, Inc. (SRPT) has a MELANY composite score of 54/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the SRPT stock rating calculated?
MELANY scores SRPT from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Sarepta Therapeutics,, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Sarepta Therapeutics,, Inc. (SRPT) Hold with a composite of 54/100 as of 2026-08-10. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the SRPT stock price forecast?
MELANY does not publish price targets or forecasts for SRPT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 54/100 across eight factors for Sarepta Therapeutics,, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is SRPT stock overvalued or undervalued?
MELANY's valuation factor currently reads 56/100 for Sarepta Therapeutics,, Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives SRPT's read.
What price should I buy SRPT at?
MELANY is not flagging a fresh entry for SRPT at its current Hold rating, so there is no entry zone to publish right now. Watchlisting SRPT in the free app gets you alerted the moment that changes.
What are the risks of buying SRPT stock?
The top risks MELANY currently flags for Sarepta Therapeutics,, Inc.: Short interest 32% of float, high volatility risk on news; Weak price momentum, trend not yet confirmed, may need more time to set up. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Sarepta Therapeutics,, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 30/100 for Sarepta Therapeutics,, Inc., and earnings track record, at 94/100. The 54/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will SRPT stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 39/100 for SRPT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this SRPT rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-10. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores SRPT continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
SRPT's live rating and alerts are free either way. The app is our flagship.